Navigation Links
Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
Date:10/21/2009

QUINCY, Mass., Oct. 21 /PRNewswire/ -- Myriant Technologies LLC (Myriant), a privately-held, biotech developer and manufacturer of renewable biochemicals, announced the formation of its Science Advisory Board and the appointment of distinguished Board members. Board members individually and collectively will provide broad insight into all aspects of the technology and business of converting renewable biomass feedstocks into valuable chemicals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091021/NE96331LOGO )

Collectively, the Board members have outstanding credentials as scientists in the biotechnology fields of specific interest to Myriant, including: molecular biology, genetic and metabolic pathway engineering, micro-organism development and related fermentation process development.

Myriant's Science Advisory Board members include:

  • Dr. Stephen J. Benkovic, Evan Pugh Professor and Eberly Chair in Chemistry at Penn State University, and member of the National Academy of Sciences and its Institute of Medicine;
  • Dr. Joseph Glas, Executive Vice President and Advisory Board Chairman, Myriant;
  • Dr. Lonnie Ingram, Distinguished Professor, Department of Microbiology and Cell Science, University of Florida, and Director, Florida Center for Renewable Chemicals and Fuels, and member of the National Academy of Sciences;
  • Dr. Jan Westpheling, Professor, Department of Genetics, University of Georgia; and
  • Dr. Huimin Zhao, Professor, Centennial Endowed Chair of Chemical and Biomolecular Engineering, University of Illinois.

"I am honored and we are fortunate to have such an exceptional group of scientists as advisors to Myriant," said Stephen J. Gatto, Chairman and Chief Executive Officer of Myriant. "Under the leadership of Dr. Joe Glas, I have great confidence that we will reap immediate and long term benefits from their advice and input."

"The pace of change in Myriant's field of industrial biotechnology is ever accelerating," added Dr. Glas. "Our cutting-edge research and development team will benefit enormously from the addition of this unique expertise and its impact on our paths to commercialization."

With a world-renowned team of molecular biologists, engineers and chemists, Myriant utilizes proprietary technology to advance the development of low-cost cellulosic sugars for the sustainable commercialization of high-value specialty chemicals. The company's D(-) lactic acid started production at commercial scale in June 2008 for use in polylactic acid. Myriant will begin commercial production of its second product, biobased succinic acid, in 2010. Myriant is headquartered in Quincy, Massachusetts. Further information is available at www.myriant.com.

    Contact: Samuel G. McConnell
    Sr. VP, Corporate Development
    617-657-5207

SOURCE Myriant Technologies LLC


'/>"/>
SOURCE Myriant Technologies LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
2. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
3. Epeius Biotechnologies to Partner at BIO Investor Forum
4. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
5. OriGene Technologies Acquires Marligen Biosciences
6. China Medical Technologies Announces the SFDA Approval for its SPR System
7. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
8. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
9. TOPAZ Technologies Protocols for Animal Studies Software Drives Customer Conversions
10. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product
11. Variation Biotechnologies Names Jeff Baxter CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a ... technology for research and clinical applications. The terms of the transaction were not ...
(Date:2/22/2017)... Scientists propose in Nature blocking a molecule ... maybe other lysosomal storage diseases as a possible treatment ... An international research team led by ... investigators from the University of L├╝beck in ... study was conducted in mouse models of lysosomal storage ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is pleased to announce ... February 22 and 23, 2017. This premier, online-only conference focused on the development ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):